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ABSTRACT
Background: Chromosome 16 open reading frame 74 (C16orf74) is highly 
expressed in pancreatic ductal adenocarcinoma (PDAC) and is involved in cancer cell 
proliferation and invasion through binding to calcineurin (CN). Therefore, C16orf74 is 
a good target for the development of a PDAC treatment. A cell-permeable dominant-
negative (DN) peptide that can inhibit the C16orf74/CN interaction was designed to 
examine whether this peptide can inhibit PDAC cell proliferation in vitro and in vivo.
Method: TheDN-C16orf74 peptide, which corresponds to the portion of C16orf74 
that interacts with CN, was synthesized, and we assessed its anti-tumor activity 
in proliferation assays with human PDAC cells and the underlying molecular 
signaling pathway. Using an orthotopic xenograft model of PDAC, we treated mice 
intraperitoneally with phosphate-buffered saline (PBS), control peptide, or DN-
C16orf74 and analyzed the tumor-suppressive effects.
Result: DN-C16orf74 inhibited the binding of C16orf74 to CN in an 
immunoprecipitation assay. DN-C16orf74 suppressed PDAC cell proliferation, and 
the level of suppression depended on the expression levels of C16orf74 in vitro. 
DN-C16orf74 also exhibited anti-tumor effects in orthotopic xenograft model. 
Furthermore, the tumor-suppressive effect was associated with inhibition of the 
phosphorylation of Akt and mTOR.
Conclusion: The cell-permeable peptide DN-C16orf74 has a strong anti-tumor 
effect against PDAC in vitro and in vivo.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one 
of the most aggressive of all malignancies [1, 2]. In 
2017, it is estimated that there will be 53,670 new cases 
of pancreatic cancer in the USA , and PDAC is the fourth 
leading cause of cancer-related death [2]. Furthermore, 
in the USA, the number of patients with PDAC is 
expected to increase to 88,000 by 2030, up from 43,000 
in 2010, which is projected to result in 63,000 deaths in 
2030 compared to 36,888 in 2010 [1]. There are several 
reasons for PDAC's high mortality. First, because it is 
difficult to uncover early-stage lesions, most PDAC is 
diagnosed at an advanced stage, and many tumors are 
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inoperable. Second, although many cytotoxic anti-cancer 
drugs, including gemcitabine (GEM), tegafur-gimestat-
otastat potassium (TS-1), and 5-fluorouracil (5-FU), 
have been developed, the subsequent improvement 
in the 5-year survival rate for PDAC patients has 
been very modest [3, 4]. The FOLFIRINOX regimen 
(fluorouracil/leucovorin plus irinotecan plus oxaliplatin) 
has demonstrated a significant survival benefit 
compared with gemcitabine for patients with metastatic 
PDAC; however, only patients who have had a good 
performance status have been treated with FOLFIRINOX 
because of a higher toxicity than other regimens [5–7]. 
A recent report has shown that nab-paclitaxel (nab-
PTX) plus GEM has controllable toxicity and superior 
efficacy than GEM alone as the first line treatment for 
patients with metastatic PDAC [8]. In this study, the 
median overall survival (OS) of the nab-paclitaxel plus 
gemcitabine group was significantly longer than that of 
the gemcitabine alone group (8.7 vs 6.6 months, hazard 
ratio [HR] = 0.72, p < 0.01) [8].
In addition, molecularly targeted therapies, such 
as receptor tyrosine kinase inhibitors, have been used to 
treat PDAC. However, gemcitabine plus erlotinib therapy 
failed to achieve a significant improvement (providing 
only a two-week extension in median OS over single-
agent gemcitabine) [9]. Moreover, there is no evidence 
supporting the use of any other molecularly targeted 
therapies in PDAC. For these reasons, the development of 
a new anti-PDAC drug with high efficacy and no/minimal/
low toxicity is urgently required.
The biological function of Chromosome 16 open 
reading frame 74 (C16orf74), which is located on 
Chromosome 16q24.1, is still not well known. However, 
we previously demonstrated that overexpression of 
the C16orf74 protein was an independent prognostic 
factor for patients with PDAC. We also showed that 
C16orf74 interacted with catalytic subunit alpha of 
protein phosphatase 3 (PPP3CA), which is an isozyme 
of calcineurin (CN), and that the interaction of these two 
proteins promoted PDAC cell proliferation and invasion 
[10]. In addition, we suggested that a CN-binding motif 
in C16orf74, PXIXIT, was critically important for PDAC 
proliferation. Hence, we hypothesized that disrupting the 
interaction between C16orf74 and CN might be a good 
approach to developing an effective treatment for PDAC.
In developing a new anti-cancer drug to inhibit the 
interaction of C16orf74 with CN, we designed a dominant-
negative C16orf74 peptide with a cell-penetrating signal. 
Several studies have evaluated cell-penetrating peptides 
(CPPs) used for drug delivery in vitro and in vivo. These 
peptides function to inhibit molecular interactions in 
cancer cells and reduce cell growth [11, 12]. In particular, 
a polyarginine sequence (11R) is known as a signal for 
uptake of peptides or proteins into cultured cells, and 
this sequence is highly efficient for inducing uptake by 
mammalian cells [13, 14].
Here, we used the newly designed cell-permeable 
peptide to inhibit the C16orf74/CN interaction, and we 
evaluated whether this peptide could inhibit the growth 
of human PDAC cells in vitro and in vivo by using an 
orthotopic xenograft mouse model and elucidated the 
molecular mechanism of the growth-suppressive effect.
RESULTS
The design of the dominant-negative C16orf74 
peptide
To design the dominant-negative C16orf74 peptide 
to inhibit the interaction between C16orf74 and CN, we 
analyzed the amino acid sequence encoded by C16orf74 
(Figure 1A) and found a CN-binding consensus sequence, 
PXIXIT (Figure 1B, 1C). A previous report indicated 
that an 11R-VIVIT peptide that included the PVIVIT 
sequence inhibited the interaction between NFAT (nuclear 
factor of activated T cells) and CN (Figure 1C, 1D) 
[15, 16]. Hence, we synthesized the peptide 11R-GGG-
KHLDVPVIVITPPTPT (DN-C16orf74; Figure 1E), in 
which the C16orf74 sequence PDIIIT was replaced with 
the sequence PVIVIT, as well as 11R-VEET as a control 
peptide (Figure 1F).
The anti-tumor effect of DN-C16orf74 on PDAC 
cells
To first examine the effect of DN-C16orf74 on the 
interaction between CN and C16orf74, we performed 
an immunoprecipitation assay. DN-C16orf74 inhibited 
the binding of C16orf74 to CN in HEK293T cells that 
had been co-transfected with a flag-tagged C16orf74 
expression vector (pCAGGS-C16orf74-3×Flag tag) and 
an HA-tagged CN expression vector (pCAGGS-CN-HA 
tag), and the inhibitory effect was dependent on the dose 
of DN-C16orf74 (Figure 2A). These results suggested that 
DN-C16orf74 inhibits the C16orf74/CN interaction in a 
dose-dependent manner.
Subsequently, to examine the growth-suppressive 
effect of DN-C16orf74 on PDAC cell lines, we 
analyzed the expression levels of C16orf74 in Capan-1, 
MIAPaCa-2, PCI43P5, and normal human dermal 
fibroblasts (NHDFs) at Real-time PCR, and found that 
Capan-1 and PCI43P5 cells expressed high levels of 
C16orf74 but that MIAPaCa-2 cells and NHDFs exhibited 
low levels of expression (Figure 2B), similar to the results 
of a western blotting analysis reported previously [10]. 
As shown in Figure 2C, 50 μM DN-C16orf74 inhibited 
the proliferation of two cell lines with high C16orf74 
expression (Capan-1 and PCI43P5) but did not notably 
inhibit the proliferation of two cell lines with low 
C16orf74 expression (MIAPaCa-2 cells and NHDFs) (p 
< 0.05). The control peptide did not exhibit a growth-
suppressive effect. Reduction rates of DN-C16orf74/
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control were as shown below, Capan-1; 0.26, PCI43P5; 
0.16, MIAPaCa-2; 0.78, and NHDF; 0.91, respectively.
Because C16orf74 contains the CN-binding 
consensus sequence present in NFAT proteins, we speculated 
that C16orf74 might activate proteins in cancer cells in a 
manner similar to NFATs. A previous report showed that 
knockdown of NFAT1 increased the phosphorylation 
levels of Akt and, conversely, overexpression of NFAT1 
or NFAT4 decreased the phosphorylation levels of Akt in 
a colorectal cancer cell line [17]. Other reports have also 
shown a relationship between NFATs and Akt in several 
organs [18–20]. Furthermore, the Akt/mTOR pathway plays 
a key role in cancer cell proliferation [21, 22]. Therefore, 
we performed western blotting to examine the expression 
levels of Akt, phospho (p)-Akt, mTOR and phospho 
(p)-mTOR, in Capan-1, MIAPaCa-2, and NDHF cells 
treated with phosphate-buffered saline (PBS) or peptide 
(Control or DN-C16orf74) (Figure 2D and Supplementary 
Figure 1). In Capan-1 with high C16orf74 expression, 
the expression levels of p-Akt and p-mTOR decreased in 
response to treatment with DN-C16orf74, while no change 
was observed in cells treated with the control peptide 
or PBS. On the other hand, in MIAPaCa-2 and NHDF 
with low C16orf74 expression, no change of p-Akt and 
p-mTOR expression levels was observed (Figure 2D and 
Supplementary Figure 1)
Anti-tumor effect of DN-C16orf74 peptide on 
human pancreatic cancer cells grown in the 
pancreas of nude mice
An orthotopic animal model was established with 
27 nude mice in which human pancreatic cancer cells 
were implanted into the pancreas, and the mice were 
divided into three groups (treatment with PBS, control 
peptide, or DN-C16orf74, n = 9 in each group). For 
these orthotopic models, Capan-1 cells (high C16orf74 
expression) were injected into the pancreas of nude 
mice [23]. Peptide treatment began 2 weeks later, when 
the tumors were considered to be established. After 
3 weeks of treatment, all mice were euthanized and 
necropsied (Figure 3A, 3B). Tumor weights (median 
weight and range) were as follows: 500 mg (300-750), 
500 mg (270-650), and 180 mg (100-390) in the PBS, 
control peptide and DN-C16orf74 groups, respectively 
(DN-C16orf74 vs PBS; p < 0.001, and DN-C16orf74 
vs control peptide; p < 0.001, Figure 3C). The body 
weights of the mice were stable, and no side effect 
was observed in any groups. Body weight (median and 
range) after two weeks were follows: 20.6g (17.3-22.0), 
21.6g (18.6-22.3), and 21.8g (19.4-22.5) in the PBS, 
control peptide and DN-C16orf74 groups, respectively. 
There was no significant difference.
Figure 1: Peptide design to inhibit the binding of C16orf74 to calcineurin (CN). (A) The C16orf74 amino acid sequence is 
shown. (B) CN-binding sequences present in C16orf74. (C) CN-binding sequences present in the NFAT (nuclear factor of activated T cells) 
family of proteins. (D) The peptide sequence of 11R-VIVIT, a blocker of NFAT/CN binding, is shown. PVIVIT is the sequence that blocks 
the binding site. The 11-arginine (R) sequence facilitates the uptake of any peptide into cultured cells with high efficiency. (E) The sequence 
of DN-C16orf74 is shown. In this peptide, the C16orf74 sequence PDIIIT has been replaced with the sequence PVIVIT, which blocks the 
CN-binding site. (F) Control peptide; 11R-VEET sequences.
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Figure 2: The anti-tumor effect of DN-C16orf74 in vitro. (A) Lysates of co-transfected HEK293T cells (pCAGGS-C16orf74-
3×Flag tag and pCAGGS-CN-HA tag) treated with DN-C16orf74 were immunoprecipitated with anti-HA antibody. Subsequently, western 
blotting analysis with anti-DDDDK (Flag) antibody detected C16orf74 and CN as co-immunoprecipitated proteins. Increasing the dose 
of DN-C16orf74 inhibited C16orf74/CN binding. The whole cell lysates showed equal expression of C16orf74 and CN in each treatment. 
IP: Immunoprecipitation, IB: Immunoblotting, WCL: Whole cell lysate. (B) The expression of C16orf74 in PDAC cell lines and NHDFs 
is shown. Capan-1 cells had very high expression of C16orf74, and PCI43P5 cells had high expression of C16orf74; MIAPaCa-2 cells 
and NHDFs had low C16orf74 expression. (C) The correlation between the anti-tumor effect of the DN-C16orf74 cell-permeable peptide 
and the C16orf74 expression pattern in PDAC cell lines and NHDFs is shown. DN-C16orf74 inhibits cell proliferation of the Capan-1 
and PCI43P5 cell lines, which have high expression of C16orf74, more than it inhibits the low-expression cell lines MIAPaCa-2 and 
NHDF. Control peptide does not inhibit cell proliferation. **: p < 0.01. (D) To analyze molecular cellular signaling after treatment with 
DN-C16orf74, western blotting analyses of the expression of Akt, phospho (p)-Akt, mTOR, phospho (p)-mTOR, and β-actin in Capan-1 
and MIAPaCa-2 cells treated with peptide were performed. In Capan-1, the expression of p-Akt and p-mTOR was decreased in response 
to treatment with DN-C16orf74, but their expression was maintained in response to treatment with the control peptide. In MIAPaCa-2, the 
expression levels were no change. The means and standard deviation (s.d.) of independent triplicate experiments in each group are shown.
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Immunohistochemical staining of Ki67, mTOR, 
p-mTOR, and TUNEL in orthotopic tumors
To further characterize the effect of DN-C16orf74 
in orthotopic tumors, we performed immunohistochemical 
staining for Ki67, mTOR, and p-mTOR (Figure 4A). 
Almost all of orthotopic tumors had C16orf74 expression 
(Supplementary Figure 2). The median Ki67-index was 
Figure 3: DN-C16orf74 treatment in an orthotopic xenograft model. (A) The treatment protocol for the orthotopic xenograft 
model is shown. Capan-1 cells (5×106) were implanted into the pancreas of BALB/c nu/nu mice. Two weeks later, the cell-permeable 
peptides (control peptide or DN-C16orf74, 9 mg/kg) or PBS were injected intraperitoneally once daily. Three weeks later, the mice were 
sacrificed. (B) Representative pancreatic tumors from the three groups (PBS, control, and DN-C16orf74) are shown. Arrowheads indicate 
pancreatic tumors. (C) Comparison of the tumor weights in the three groups. The dot plots (n = 9, respectively) represent tumor weight, 
and the bars represent the medians. Tumors treated with DN-C16orf74 were significantly smaller than the other tumors (vs. PBS; p < 0.001, 
and vs control; p < 0.001).
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w37.9% (range, 21.1-42.0%) in the PBS group and 32.5% 
(range, 23.1-44.5%) in the control peptide group, but 
that in the DN-C16orf74 group was significantly lower, 
23.3% (range, 12.1-29.3%) (vs the PBS group; p < 0.001, 
and vs the control peptide group; p < 0.01, Figure 4B). 
In addition, the median p-mTOR/mTOR ratio was 0.84 
(range, 0.66-0.94) in the PBS group and 0.97 (range, 
0.71-1.11) in the control peptide group, but that in the 
Figure 4: Analysis of cell proliferation (Ki67), mTOR, and p-mTOR in pancreatic tumors from peptide-treated mice. 
(A) Immunohistochemical staining for Ki67, mTOR, and p-mTOR in pancreatic tumors treated with PBS, control peptide, or DN-C16orf74 
is shown. Scale bars, 100 μm. (B) Comparison of the Ki67 index of the three groups. The Ki67 index is expressed as the percentage of 
Ki67-positive cells. The dot plots (n = 9, respectively) represent the Ki67 index, and the bars represent the medians. The Ki67 index is 
significantly lower in the DN-C16orf74 group than in the other groups (vs. PBS; p < 0.001, vs control; p < 0.01). (C) Comparison of the 
p-mTOR/mTOR expression ratio of the three groups. The dot plots (n = 9, respectively) represent the ratio, and the bars represent the 
medians. The ratio is significantly lower in the DN-C16orf74 group than in the other groups (vs. PBS; p < 0.001, vs control; p < 0.001).
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DN-C16orf74 group was significantly lower, 0.47 (range, 
0.18-0.67) (vs the PBS group; p < 0.001, and vs the 
control peptide group; p < 0.001, Figure 4C). Furthermore, 
regression analysis showed significant correlation 
between orthotopic tumor weight and p-mTOR/mTOR 
ratio (r=0.701, p<0.001, Supplementary Figure 3). 
On the other hand, the median TUNEL numbers of the 
three groups were not significantly different respectively 
(Supplementary Figure 4).
DISCUSSION
This study clearly indicates that the peptide DN-
C16orf74, which corresponds to a portion of C16orf74, 
can inhibit the C16orf74/CN interaction in a dose-
dependent manner and suppress PDAC cell proliferation 
in vitro and in vivo. Previous report showed that 46 
PDAC cases (56.8%) had C16orf74 overexpression by 
immunohistochemical staining of a tissue microarray in 
81 PDAC cases that underwent curative surgical resection, 
and these patients had poor prognosis rather than low 
expression patients [10]. This growth-suppressive effect 
was observed in PDAC cell lines showing high C16orf74 
expression although the molecular mechanism by which 
the C16orf74/CN pathway can control cell growth is 
not clear. Because C16orf74 contains the consensus 
CN-binding sequence present in NFAT proteins, we 
hypothesized that C16orf74 might activate certain 
signaling pathways in cancer cells in a fashion similar 
to NFATs, and previous reports indicate a relationship 
between NFATs and Akt signaling [18–20]. Akt, a serine/
threonine kinase, is a key regulator of cancer cell survival 
and proliferation and is an ideal target for the development 
of anti-cancer drugs [24, 25]. The phosphatidylinositol-
3-kinase (PI3K)/Akt/mTOR pathway is also an important 
molecular signaling pathway in the regulation of tumor 
cell proliferation [26]. Therefore, we suspected that the 
C16orf74/CN interaction might be involved in the Akt/
mTOR pathway and analyzed these molecules in vitro and 
in vivo. Our results indicate that DN-C16orf74 can inhibit 
C16orf74/CN binding in vitro and in vivo, and this resulted 
in suppression of the phosphorylation of Akt and mTOR, 
although further analysis will be necessary to determine 
the relationship between the C16orf74/CN interaction and 
the PI3K/Akt/mTOR pathway in the growth of PDAC.
The polyarginine sequence in DN-C16orf74 
facilitates highly efficient nonspecific uptake of peptides 
into cells [14, 16]. Therefore, caution would be needed if 
DN-C16orf74 were used in the clinic because systemic 
peptide administration might not achieve a sufficient 
concentration in tumor tissue owing to uptake by 
normal vascular endothelial cells in blood vessels. Thus, 
cancer-specific peptide delivery systems are critical in 
considering the possibility of developing DN-C16orf74 
for clinical use. In this regard, cancer cell-specific 
cell-permeable peptide signals, which can penetrate 
only the target cells in vitro and in vivo [27], might be 
applicable. If the polyarginine sequences in DN-C16orf74 
peptide were modified to pancreatic cancer cell-specific 
penetrating sequences, a high-dose of DN-C16orf74 could 
be administered more effectively and safely. In addition, 
peptide stability in the blood is an important issue. For 
example, the peptide drug Calperitide (α-human A-type 
natriuretic peptide) is used in the clinic, but since the 
half-life of this peptide is very short [28], therefore, DN-
C16orf74 peptide has been modified to make it more 
stable in the blood. The other possibility for clinical use 
of DN-C16orf74 is direct injection of the peptide into 
the pancreatic tumor via endoscopic ultrasound (EUS)-
guided fine needle injection, which has been attempted 
for various agents, including oncolytic virus, mixed 
lymphocyte culture, and immature dendritic cells [29, 
30]. In addition, intraperitoneal administration of this 
peptide may be considered for pancreatic cancer patients 
with peritoneal dissemination. Recently, a phase II clinical 
trial of intraperitoneal paclitaxel for PDAC patients with 
peritoneal metastasis was reported [31]. This report 
showed that the median survival time for treated patients 
was 16.3 (11.47-22.57) months, and approximately 30% 
of the patients underwent conversion surgery after control 
of the peritoneal dissemination.
In conclusion, DN-C16orf74 inhibited the 
C16orf74/CN interaction in a dose-dependent manner 
and suppressed PDAC proliferation in vitro and in vivo 
through reduction of Akt and mTOR phosphorylation. 
C16orf74 could be an ideal molecular target for PDAC 
treatment, and DN-C16orf74 is a potential drug candidate 
for use as a C16orf74 inhibitor.
MATERIALS AND METHODS
Peptide design and synthesis
Three peptides were synthesized by Sigma Life 
Science (Tokyo, Japan). The amino acid sequences of the 
peptides are shown below.
DN-C16orf74; RRRRRRRRRRR-GGG-KHLD 
VPVIVIPPTPT
11R-VIVIT; RRRRRRRRRRR-GGG-MAGP 
HPVIVITGPHEE
11R-VEET; RRRRRRRRRRR-GGG-MAGP 
PHIVEETGPHVI
The peptide 11R-VEET is non-functional and 
was used as the control peptide [16]. The peptides 
were purified by preparative reversed-phase HPLC and 
were >90.5% pure, and had the expected amino acid 
compositions and mass spectra.
Cell lines
The human PDAC cell lines Capan-1 and 
MIAPaCa-2 and the embryonic kidney cell line 
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HEK293T were purchased from the American Type 
Culture Collection (ATCC, Rockville, MD, USA). 
NHDFs were purchased from TAKARA BIO (Shiga, 
Japan). The PCI43P5 cell line was previously established 
from surgically resected PDAC tissues at our institute 
[32]. All cell lines were cultured in the appropriate 
medium as directed by the manufacturers or according 
to published studies. Capan-1 was cultured in IMDM 
(WAKO, Tokyo, Japan) with 20% fetal bovine serum 
(Cell Culture Bioscience), and 1% penicillin/streptomycin 
(Life Technologies), and MIAPaCa-2, PCI43P5, NHDF, 
and HEK293T cells were cultured in RPMI 1640 
(WAKO) with 10% fetal bovine serum, and 1% penicillin/
streptomycin. All cells were incubated at 37°C in a 
mixture of 5% CO2 and 95% air.
Real-time PCR
Total RNA was extracted with an RNAeasy Mini 
Kit (Qiagen), and cDNA was synthesized with PrimeScript 
RT Master Mix (TAKARA BIO). Real-time PCR was 
performed with Fast SYBR ® Green Master Mix (Life 
Technologies) and specific primers (Supplementary Table 
1), and the products were analyzed using StepOne (Applied 
Biosystems). Each peak in the melting curve was validated 
for primer specificity. All experiments were performed in 
duplicate for each sample. Gene expression was normalized 
to GAPDH expression, and fold expression changes were 
calculated using the ΔΔCt method. A list of the primers is 
provided in Supplementary Table 1.
Western blotting and immunoprecipitation
Total cell lysate protein samples were collected 
with RIPA buffer in the presence of the protease inhibitors 
aprotinin (WAKO) and phenylmethylsulfonyl fluoride 
(PMSF, WAKO). Recombinant C16orf74 protein was 
produced in our laboratory. Samples were resolved using 
15% SDS-PAGE and then transferred to PVDF membranes 
(Bio-RAD, Tokyo, Japan). Membranes were probed with 
primary antibodies against the targets followed by goat 
anti-mouse or rabbit IgG as the secondary antibodies 
(1:10,000 dilution). Primary antibodies and dilutions 
are shown in Supplementary Table 2, and secondary 
antibodies were purchased from Jackson ImmunoResearch. 
Immunoreactivity was detected with an enhanced 
chemiluminescence detection system (GE Healthcare). 
Equal loading was confirmed with β-actin. A list of the 
antibodies is presented in Supplementary Table 2.
For the immunoprecipitation assay, co-transfected 
HEK293T cells (pCAGGS-C16orf74-3×Flag tag and 
pCAGGS-CN-HA tag) were treated with DN-C16orf74 
peptide (0, 25, or 50 μM) for 12-24 hours and lysed with 
RIPA buffer [10]. Immunoprecipitation was performed 
with mouse anti-HA antibody (Medical and Biological 
Laboratories, Nagoya, Japan). The antibodies were 
removed by incubation with Protein A-Agarose (sc-2001; 
Santa Cruz Biotechnology, Santa Cruz, CA), and the wash 
step was repeated 5 times. Proteins were extracted with 
SDS sample buffer and separated by 10-20% gradient 
SDS-PAGE (Bio-Rad). To examine the interaction 
between Flag-C16orf74 and HA-CN, we analyzed the 
immune complexes using western blotting with mouse 
anti-DDDDK(Flag)-tag antibody (Medical and Biological 
Laboratories) and anti-HA antibody.
Cell proliferation assay (WST assay)
Cell proliferation was assessed after treatment using 
Cell Counting Kit-8 (WST-8, DOJINDO, Kumamoto, 
Japan). Cell lines were used in this assay; 5×103 cells were 
seeded in 96-well plates and cultured for 24 hours before 
treatment. Cells were treated with control peptide or DN-
C16orf74 (50 μM) or PBS as the control for 24 hours. At 4 
hours after WST-8 application, absorbance was measured 
at 450 nm using a microplate reader. The viability of cells 
treated with PBS was set at 100%, and the absorbance of 
wells with medium but without cells was set to zero.
Treatment of the cells with peptides to analyze 
molecular signaling
To analyze how molecular signaling in PDAC cells 
was affected by DN-C16orf74, total cell lysate protein 
samples were collected from Capan-1, MIAPaCa-2 and 
NHDF cells treated with each of two peptides. The cells 
were treated for 6 hours with 25 μM peptide (a control 
peptide or DN-C16orf74) or PBS as a control, and protein 
samples were collected. Western blotting analyses of Akt, 
p-Akt, mTOR, p-mTOR, and β-actin were performed.
Immunohistochemical staining
Immunohistochemical staining of xenograft tumors 
was performed as previously described [33]. All samples 
were formalin-fixed and paraffin-embedded. Primary 
antibodies, dilutions, and antigen retrieval methods are 
shown in Supplementary Table 2. Negative controls were 
established by not adding primary antibody. All specimens 
were evaluated by two investigators (S.S. and H.T.). 
For Ki67 expression, staining was considered positive 
when nuclear staining was observed. The Ki67-index is 
expressed as the percentage of Ki67-positive cells in three 
independent high-power (200×) microscopic fields for 
each tissue sample. For mTOR and p-mTOR expression, 
staining was considered positive when cytoplasmic 
staining was observed. Analysis of the p-mTOR/mTOR 
ratio was performed in three independent high-power 
microscopic fields for each tissue sample. For apoptosis 
analysis, a TUNEL assay was performed using a 
commercially available TUNEL kit, the Apoptosis in situ 
Oncotarget113670www.impactjournals.com/oncotarget
Detection Kit Wako (WAKO). A list of the antibodies is 
presented in Supplementary Table 2.
Animals and implantation of tumor cells for 
orthotopic xenografts
Capan-1 cells were harvested from subconfluent 
cultures by brief exposure to 0.25% trypsin. 
Trypsinization was stopped with medium containing 
10% FBS, and cells were resuspended in Hank's 
balanced salts solution (HBSS, Life Technologies). 
For mouse studies, female BALB/c-nu/nu mice were 
purchased from CLEA, Japan. At the age of 6-8 
weeks, mice were anesthetized, and a left subcostal 
incision was made. Capan-1 cells were resuspended 
(5×106/100 μl HBSS) and injected subcapsularly into a 
region of the pancreas just beneath the spleen through 
the subcostal incision. A 27-gauge needle and a 1-mL 
disposable syringe were used. A successful subcapsular 
intrapancreatic injection of tumor cells was identified 
by the appearance of a fluid bleb without intraperitoneal 
leakage. To prevent such leakage, a cotton swab was 
held for 30 seconds over the injection site. One layer 
of the abdominal wound was closed with wound clips 
(Auto-clip; Clay Adams, Parsippany, NJ) [34]. The 
animals tolerated the surgical procedure well, and no 
anesthesia-related deaths occurred. Animal procedures 
were conducted according to the guidelines of the 
Hokkaido University Institutional Animal Care and Use 
Committee using an approved protocol.
Peptide treatment protocol for orthotopic 
xenograft model
Starting two weeks after implantation of Capan-1 
cells, the mice were intraperitoneally injected with 
DN-C16orf74 peptide or control peptide (9 mg/kg, 0.5 
ml) (using a 27-gauge needle and a 1-mL disposable 
syringe) once daily for 3 weeks. As a negative control, 
the same volume of PBS was used. The mice were 
sacrificed under anesthesia approximately 24 hours after 
the final injection of peptide or PBS, and the pancreatic 
tumors were resected. After the tumors were weighed 
(mg), they were fixed in 10% formalin and embedded 
in paraffin wax for immunohistochemical staining 
procedures.
Statistical analysis
All analyses were performed using StatFlex 6.0 
software (Artech Co., Osaka, Japan). Student’s t-test, a chi-
square test, and Fisher’s exact test were used for comparisons, 
as appropriate. The relationship between orthotopic tumor 
weight and p-mTOR/mTOR ratio was evaluated using the 
coefficient of determination (r) in the goodness of fit model. 
Results were considered significant at p < 0.05.
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